Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Voyager Therapeutics (VYGR) Treasury Shares (2016 - 2025)

Voyager Therapeutics' Treasury Shares history spans 11 years, with the latest figure at $2.3 million for Q4 2025.

  • For Q4 2025, Treasury Shares rose 39.21% year-over-year to $2.3 million; the TTM value through Dec 2025 reached $2.3 million, up 39.21%, while the annual FY2025 figure was $2.3 million, 39.21% up from the prior year.
  • Treasury Shares for Q4 2025 was $2.3 million at Voyager Therapeutics, down from $2.5 million in the prior quarter.
  • Across five years, Treasury Shares topped out at $2.8 million in Q1 2025 and bottomed at $806379.0 in Q4 2021.
  • The 5-year median for Treasury Shares is $1.4 million (2023), against an average of $1.6 million.
  • The largest annual shift saw Treasury Shares soared 115.05% in 2021 before it tumbled 31.7% in 2022.
  • A 5-year view of Treasury Shares shows it stood at $806379.0 in 2021, then surged by 37.97% to $1.1 million in 2022, then increased by 23.22% to $1.4 million in 2023, then rose by 20.35% to $1.6 million in 2024, then surged by 39.21% to $2.3 million in 2025.
  • Per Business Quant, the three most recent readings for VYGR's Treasury Shares are $2.3 million (Q4 2025), $2.5 million (Q3 2025), and $2.7 million (Q2 2025).